Rare disease drug approval inconsistencies
Discussed in 1 analyzed podcast episode across 1 show
Discussed On
Episodes
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher programCBER and CDER leadership vacanciesPharma CEO compensation analysis 2025
View Analysis